Gardasil and Bridion: Merck’s High-Growth Assets

Bridion growth trends

In the first quarter, sales of Merck’s (MRK) hospital acute care drug, Bridion, rose 25% YoY (year-over-year) on a reported basis and 30% on a CC (constant-currency) basis to $255 million. In fiscal 2018, Bridion revenue rose 30% YoY to $917 million on a reported and CC basis. In its first-quarter conference call, Merck stated that Bridion’s increasing use in US markets as a neuromuscular reversal agent in surgical procedures has been its driving force in fiscal 2019.

Gardasil and Bridion: Merck’s High-Growth Assets

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Gardasil/Gardasil 9

In the first quarter, sales of Merck’s human papillomavirus vaccine, Gardasil/Gardasil 9, rose 27% YoY on a reported basis and 31% YoY on CC basis to $838 million. In fiscal 2018, Gardasil/Gardasil 9 revenue rose 37% YoY on a reported basis and 36% YoY on a CC basis to $3.15 billion. Merck stated in its first-quarter press release that increased uptake due to its Chinese launch, gender-neutral vaccination in Europe, and public-sector purchases in Latin America drove demand for the vaccine in fiscal 2019.

V114 vaccine program

Merck expects the first data readout from its registrational Phase 3 program evaluating its pneumococcal conjugate vaccine, V114, in fiscal 2019. If approved by the FDA, the vaccine could be a solid revenue driver for Merck in future years. To learn about AbbVie’s key a growth drivers, read AbbVie’s Guidance for the Second Quarter of Fiscal 2019.